JP2021535920A5 - - Google Patents

Info

Publication number
JP2021535920A5
JP2021535920A5 JP2021513792A JP2021513792A JP2021535920A5 JP 2021535920 A5 JP2021535920 A5 JP 2021535920A5 JP 2021513792 A JP2021513792 A JP 2021513792A JP 2021513792 A JP2021513792 A JP 2021513792A JP 2021535920 A5 JP2021535920 A5 JP 2021535920A5
Authority
JP
Japan
Prior art keywords
compound according
optionally substituted
compound
group
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021513792A
Other languages
English (en)
Japanese (ja)
Other versions
JP7675648B2 (ja
JP2021535920A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2019/057715 external-priority patent/WO2020053815A1/en
Publication of JP2021535920A publication Critical patent/JP2021535920A/ja
Publication of JP2021535920A5 publication Critical patent/JP2021535920A5/ja
Priority to JP2024182071A priority Critical patent/JP2025023928A/ja
Application granted granted Critical
Publication of JP7675648B2 publication Critical patent/JP7675648B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021513792A 2018-09-12 2019-09-12 放出可能なglp-1コンジュゲート Active JP7675648B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024182071A JP2025023928A (ja) 2018-09-12 2024-10-17 放出可能なglp-1コンジュゲート

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862730341P 2018-09-12 2018-09-12
US62/730,341 2018-09-12
US201862730935P 2018-09-13 2018-09-13
US62/730,935 2018-09-13
US201862771972P 2018-11-27 2018-11-27
US62/771,972 2018-11-27
PCT/IB2019/057715 WO2020053815A1 (en) 2018-09-12 2019-09-12 Releasable glp-1 conjugates

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024182071A Division JP2025023928A (ja) 2018-09-12 2024-10-17 放出可能なglp-1コンジュゲート

Publications (3)

Publication Number Publication Date
JP2021535920A JP2021535920A (ja) 2021-12-23
JP2021535920A5 true JP2021535920A5 (enExample) 2022-09-20
JP7675648B2 JP7675648B2 (ja) 2025-05-13

Family

ID=68382464

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021513792A Active JP7675648B2 (ja) 2018-09-12 2019-09-12 放出可能なglp-1コンジュゲート
JP2024182071A Pending JP2025023928A (ja) 2018-09-12 2024-10-17 放出可能なglp-1コンジュゲート

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024182071A Pending JP2025023928A (ja) 2018-09-12 2024-10-17 放出可能なglp-1コンジュゲート

Country Status (10)

Country Link
US (3) US11357828B2 (enExample)
EP (1) EP3849660A1 (enExample)
JP (2) JP7675648B2 (enExample)
KR (1) KR20210057130A (enExample)
CN (1) CN112955216A (enExample)
AU (2) AU2019340472A1 (enExample)
BR (1) BR112021004689A2 (enExample)
CA (1) CA3112473A1 (enExample)
TW (1) TWI834720B (enExample)
WO (1) WO2020053815A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110545850A (zh) * 2017-03-10 2019-12-06 奎亚培格制药公司 可释放的缀合物
EP3849660A1 (en) 2018-09-12 2021-07-21 QuiaPEG Pharmaceuticals AB Releasable glp-1 conjugates
CA3184998A1 (en) 2020-08-05 2022-02-10 Samuel WEISBROD Conjugates comprising reversible linkers and uses thereof
US20230372539A1 (en) * 2020-08-24 2023-11-23 The Trustees Of The University Of Pennsylvania Viral vectors encoding glp-1 receptor agonist fusions and uses thereof in treating metabolic diseases
CN113430154A (zh) * 2021-05-21 2021-09-24 深圳市前海金卓生物技术有限公司 分泌glp-1的蛋白表达系统及其制备方法和应用
WO2024079739A1 (en) * 2022-10-14 2024-04-18 Bhami's Research Laboratory, Pvt. Ltd. Polypeptide formulations for oral delivery
JPWO2024101446A1 (enExample) * 2022-11-10 2024-05-16
IL323019A (en) * 2023-03-06 2025-10-01 Ascendis Pharma As Drug compounds with an albumin-binding moiety
US20260007869A1 (en) 2023-06-23 2026-01-08 Vaxess Technologies, Inc. Microneedle array patches (maps), systems, and methods for manufacturing and using same

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4647447A (en) 1981-07-24 1987-03-03 Schering Aktiengesellschaft Diagnostic media
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
EP0563475B1 (en) 1992-03-25 2000-05-31 Immunogen Inc Cell binding agent conjugates of derivatives of CC-1065
US5395619A (en) 1993-03-03 1995-03-07 Liposome Technology, Inc. Lipid-polymer conjugates and liposomes
US5994341A (en) 1993-07-19 1999-11-30 Angiogenesis Technologies, Inc. Anti-angiogenic Compositions and methods for the treatment of arthritis
US5637684A (en) 1994-02-23 1997-06-10 Isis Pharmaceuticals, Inc. Phosphoramidate and phosphorothioamidate oligomeric compounds
EP1275635A1 (en) 1994-10-21 2003-01-15 Nps Pharmaceuticals, Inc. Calcium receptor-active compounds
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US5817856A (en) 1995-12-11 1998-10-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem Radiation-protective phospholipid and method
US5830600A (en) 1996-05-24 1998-11-03 Sri International Nonflammable/self-extinguishing electrolytes for batteries
JPH10175987A (ja) 1996-12-13 1998-06-30 Nof Corp 重合性基含有有機リン酸エステル化合物およびその製造方法
US6180095B1 (en) 1997-12-17 2001-01-30 Enzon, Inc. Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
US5922897A (en) 1998-05-29 1999-07-13 Xerox Corporation Surfactant processes
US20030165849A1 (en) 2000-11-28 2003-09-04 Biliang Zhang Methods and reagents for introducing a sulfhydryl group into the 5'-terminus of RNA
US6320041B1 (en) 2001-04-13 2001-11-20 Trilink Biotechnologies, Inc. Pre-activated carbonyl linkers for the modification of oligonucleotides
US6743905B2 (en) 2001-04-16 2004-06-01 Applera Corporation Mobility-modified nucleobase polymers and methods of using same
CA2446904A1 (en) 2001-05-24 2003-04-03 Alexza Pharmaceuticals, Inc. Delivery of drug esters through an inhalation route
US20100240730A1 (en) 2002-02-20 2010-09-23 Merck Sharp And Dohme Corp. RNA Interference Mediated Inhibition of Gene Expression Using Chemically Modified Short Interfering Nucleic Acid (siNA)
US20040062748A1 (en) 2002-09-30 2004-04-01 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
EP1594440B1 (en) 2003-02-14 2019-07-03 Quanta Biodesign, Ltd. The selective and specific preparation of discrete peg compounds
ES2605443T3 (es) 2003-11-06 2017-03-14 Seattle Genetics, Inc. Conjugados de auristatina con anticuerpos anti-HER2 o anti-CD22 y su uso en terapia
US20070276139A1 (en) 2004-02-10 2007-11-29 Quanlai Song Substituted Pixyl Protecting Groups for Oligonucleotide Synthesis
CA2786794C (en) 2004-03-23 2017-09-12 Complex Biosystems Gmbh Aromatic polymeric cascade prodrug linker reagent
US8410047B2 (en) * 2004-06-11 2013-04-02 Novo Nordisk A/S Counteracting drug-induced obesity using GLP-1 agonists
US20060063147A1 (en) 2004-09-21 2006-03-23 Chernov Boris K Omega-amino-PEG-phosphoramidites and conjugates thereof
TW200612993A (en) 2004-10-08 2006-05-01 Alza Corp Lipopolymer conjugates
CN101291684A (zh) 2005-10-21 2008-10-22 阿维季尼克斯股份有限公司 甘醇化和糖基化的禽类来源的治疗性蛋白
WO2007055789A2 (en) 2005-10-31 2007-05-18 Neose Technologies, Inc. Expression of soluble therapeutic proteins
WO2007059912A1 (en) 2005-11-23 2007-05-31 Roche Diagnostics Gmbh Polynucleotide labelling reagent
WO2007075534A2 (en) * 2005-12-16 2007-07-05 Nektar Therapeutics Al, Corporation Polymer conjugates of glp-1
JP5140824B2 (ja) 2006-04-19 2013-02-13 国立大学法人 東京大学 リゾホスファチジルスレオニンおよびその誘導体
US7985783B2 (en) 2006-09-21 2011-07-26 The Regents Of The University Of California Aldehyde tags, uses thereof in site-specific protein modification
JP5411703B2 (ja) 2006-11-09 2014-02-12 アルコン リサーチ, リミテッド 薬物送達のための水不溶性ポリマーマトリクス
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
US20130195888A1 (en) 2007-11-30 2013-08-01 Abbvie Ultrafiltration and diafiltration formulation methods for protein processing
LT2237799T (lt) 2008-02-01 2019-07-25 Ascendis Pharma A/S Provaistas, apimantis besiskaidantį linkerį
TWI451876B (zh) 2008-06-13 2014-09-11 Lilly Co Eli 聚乙二醇化之離脯胰島素化合物
EP2310440A4 (en) 2008-07-10 2013-06-05 Serina Therapeutics Inc POLYOXAZOLINES WITH INTERNAL END GROUPS, POLYOXAZOLINES MANUFACTURED FROM PROTECTED INITIAL GROUPS AND CORRESPONDING COMPOUNDS
US20110206633A1 (en) 2008-09-19 2011-08-25 Nektar Therapectics Polymer conjugates of cd-np peptides
EP2432489B1 (en) 2009-05-20 2016-10-05 BioMarin Pharmaceutical Inc. Variants of c-type natriuretic peptide
US9173953B2 (en) 2009-07-31 2015-11-03 Ascendis Pharma As Prodrugs containing an aromatic amine connected by an amido bond to a linker
US9062094B2 (en) 2010-01-22 2015-06-23 Ascendis Pharma As Dipeptide-based prodrug linkers for aliphatic amine-containing drugs
CN103003300B (zh) * 2010-04-27 2017-06-09 西兰制药公司 Glp‑1受体激动剂和胃泌素的肽缀合物及其用途
WO2011140393A1 (en) 2010-05-05 2011-11-10 Prolynx Llc Controlled release from macromolecular conjugates
WO2012019188A2 (en) 2010-08-06 2012-02-09 The Regents Of The University Of Colorado, A Body Corporate Methods and compositions for the inhibition of fructokinase
AU2011342896A1 (en) * 2010-12-13 2013-07-04 Quiapeg Pharmaceuticals Ab Functionalized polymers
CN107365339A (zh) 2011-07-19 2017-11-21 波涛生命科学有限公司 合成官能化核酸的方法
EP3643306A3 (en) 2011-08-12 2020-08-26 Ascendis Pharma A/S Carrier-linked prodrugs having reversible carboxylic ester linkages
CN102321170B (zh) * 2011-09-14 2013-11-13 深圳翰宇药业股份有限公司 利拉鲁肽变构体及其缀合物
AU2013276219B2 (en) 2012-06-12 2018-03-08 Quiapeg Pharmaceuticals Ab Conjugates of biologically active molecules to functionalized polymers
EP2910573B1 (en) 2012-10-19 2020-02-19 Daiichi Sankyo Company, Limited Antibody-drug conjugate produced by binding through linker having hydrophilic structure
CN105813653B (zh) * 2013-12-19 2020-06-26 西雅图基因公司 与目标-药物偶联物并用的亚甲基氨基甲酸酯连接物
AR100639A1 (es) * 2014-05-29 2016-10-19 Hanmi Pharm Ind Co Ltd Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada
CA2952834A1 (en) * 2014-06-20 2015-12-23 Abgenomics International Inc. Her2 antibody-drug conjugates
JP6369721B2 (ja) 2014-07-04 2018-08-08 国立大学法人 東京大学 リゾホスファチジルセリン誘導体
CN104725628B (zh) 2014-10-01 2018-04-17 厦门赛诺邦格生物科技股份有限公司 一种含可降解基团的单一官能化支化聚乙二醇、制备方法及其生物相关物质
SG10202011002WA (en) 2015-01-09 2020-12-30 Ascendis Pharma Growth Disorders As Cnp prodrugs
WO2016145536A1 (en) 2015-03-18 2016-09-22 Immunobiochem Corporation Conjugates for the treatment of cancer targeted at intracellular tumor-associated antigens
ES2907651T3 (es) 2015-08-14 2022-04-25 Remegen Biosciences Inc Enlazadores covalentes en conjugados de anticuerpo-fármaco y métodos para obtener y usar los mismos
US10835578B2 (en) 2016-01-08 2020-11-17 Ascendis Pharma Growth Disorders A/S CNP prodrugs with large carrier moieties
JP6968802B2 (ja) 2016-01-08 2021-11-17 アセンディス ファーマ グロース ディスオーダーズ エー/エス 環部分にキャリア結合を有するcnpプロドラッグ
GB201607827D0 (en) 2016-05-04 2016-06-15 Bicycle Therapeutics Ltd Bicyclic peptide-toxin conjugates specific for MT1-MMP
ES2985986T3 (es) 2017-01-06 2024-11-08 Bicyclerd Ltd Conjugado biciclo para tratar el cáncer
BR102017004833A2 (pt) 2017-03-10 2018-10-30 Leite Miguel produto bactericida/germicida/fungicida/esporocida extraído dos ácidos graxos a ser administrado via oral em animais de criação monogástricos e/ou ruminantes e método de obtenção
CN110545850A (zh) 2017-03-10 2019-12-06 奎亚培格制药公司 可释放的缀合物
BR112020015071A2 (pt) 2018-03-09 2021-01-05 Quiapeg Pharmaceuticals Ab Conjugados de anticorpos liberáveis
EP3849660A1 (en) 2018-09-12 2021-07-21 QuiaPEG Pharmaceuticals AB Releasable glp-1 conjugates

Similar Documents

Publication Publication Date Title
JP2020512302A5 (enExample)
ES2260859T3 (es) Profarmacos polimericos con bloqueo trialquilo facilitado de agentes bioactivos que contienen amino.
CA2388468A1 (en) Mediators of hedgehog signalling pathways, compositions and uses related thereto
CA2513440A1 (en) Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
US6815542B2 (en) Nucleoside compounds and uses thereof
KR100270806B1 (ko) 5-플루오로-2`-데옥시-3`-티아시티딘을 함유하는 b형 간염 치료를 위한 약제
US20020055473A1 (en) Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
JP2019104739A (ja) Sn−38の徐放性コンジュゲート
AR067181A1 (es) Inhibidores de transcriptasa inversa de hiv, composicion farmaceutica, uso del compuesto para preparar un medicamento, agente de combinacion farmaceutica y metodo de inhibicion de la replicacion de un retrovirus
HUP0203841A2 (en) 5-membered heteroaromatic compounds and use thereof for preparation of pharmaceutical compositions, and pharmaceutical compositions containing them
JP2005505565A5 (enExample)
JP2002517491A5 (enExample)
RU2008152171A (ru) Новые ингибиторы вирусной репликации гепатита с
CA2632626A1 (en) Ester prodrugs of 2'-fluoro-2'-alkyl-2'-deoxycytidines and their use in the treatment of hcv infection
KR940011475A (ko) 신규한 에리트로마이신 유도체, 그의 제조 방법 및 의약으로서의 그의 용도
JP2005535564A5 (enExample)
EP1121369B1 (en) Ribavirin-interferon alfa combination therapy for eradicating detectable hcv-rna in patients having chronic hepatitis c infection
JPH09216824A (ja) クラミジア感染症治療剤
US20030004119A1 (en) Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
KR960022472A (ko) 3-페닐이소퀴놀-1(2h)-온 유도체와 그것의 제법 및 치료학적 이용
FR2711139B1 (fr) Nouveaux dérivés de 1,2,3,4-tétrahydronaphtalène, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
KR920000730A (ko) 신규 벤즈이미다졸 유도체, 그의 제조방법, 그의 신규 중간체, 그의 약물 용도 및 그를 함유하는 제약 조성물
KR950703557A (ko) 약제로서 사용되는 헤테로아릴 화합물(Heteroaryl Compounds Used as Pharmaceuticals)
CA2452920A1 (en) Benzo [g] quinoline derivatives for treating glaucoma and myopia
JP2005514440A5 (enExample)